drugset
Drugs / Pegylated Recombinant Human Hyaluronidase PH20
last change Oct 2022 re-read 3 minutes ago

Pegylated Recombinant Human Hyaluronidase PH20

also known as Pegvorhyaluronidase Alfa

Protein / enzyme biologic

Developed for
pancreatic adenocarcinoma
Investigated by
M.D. Anderson Cancer Center · National Cancer Institute (NCI)

Trials 1

today NCT04058964 · Ph 2
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04058964 Feb 2020 → Oct 2022 pancreatic adenocarcinoma M.D. Anderson Cancer Center Withdrawn No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Pegylated Recombinant Human Hyaluronidase PH20 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04058964 ↗
Known as Pegvorhyaluronidase Alfa “PEGPH20 (Pegvorhyaluronidase Alfa)” NCT04058964 ↗
Modality Protein / enzyme biologic “PEGPH20 is an enzyme that breaks down hyaluronic acid coating tumor cells” NCT04058964 ↗
Route Subcutaneous “pegylated recombinant human hyaluronidase PH20 subcutaneously (SC)” NCT04058964 ↗